- The disease
- Alzheimer's disease is a progressive neurodegenerative condition characterised by memory loss and cognitive decline, and is the most common form of dementia globally. Motor neurone disease (MND), also called amyotrophic lateral sclerosis (ALS), is a fatal neurodegenerative disease in which the nerve cells controlling muscle movement progressively break down. Both conditions currently lack disease-modifying treatments that halt or reverse neurodegeneration. There are no approved therapies that fully stop progression in either indication.
- What the asset is trying to do
- EmtinB is a peptide therapeutic described by Neuroscientific Biopharmaceuticals as a metal-attenuating peptide. Its proposed mechanism involves binding copper and zinc ions to prevent those metals from interacting with proteins such as amyloid-beta in Alzheimer's disease or other misfolded proteins in MND, where such metal-protein interactions are thought to contribute to toxic aggregation. This approach differs from antibody-based amyloid-clearing therapies (such as anti-amyloid monoclonal antibodies) and from gene-silencing approaches in that it targets the metal-ion chemistry rather than the protein itself or its genetic source. The asset is at preclinical stage, meaning it has not yet entered human clinical trials.
- Efficacy benchmarks in this setting
- For Alzheimer's disease, lecanemab (Leqembi) demonstrated a 27% slowing of clinical decline on the CDR-SB (Clinical Dementia Rating Sum of Boxes) scale versus placebo in the CLARITY AD Phase 3 trial (van Dyck et al, New England Journal of Medicine, 2023). Donanemab showed a 35% slowing of decline on the iADRS (Integrated Alzheimer's Disease Rating Scale) versus placebo in the TRAILBLAZER-ALZ 2 Phase 3 trial (Sims et al, JAMA, 2023). For MND/ALS, riluzole extended median survival by approximately two to three months versus placebo in its registration trial (Bensimon et al, New England Journal of Medicine, 1994). Edaravone reduced functional decline by 33% on the ALSFRS-R scale in a selected ALS population in a Phase 3 trial (Writing Group on behalf of the Edaravone ALS 19 Study Group, Lancet Neurology, 2017). EmtinB is at preclinical stage and has not generated human efficacy data; any preclinical figures are not statistically comparable to results from randomised controlled trials in human populations.
- Commercial context
- In Alzheimer's disease, the US Food and Drug Administration (FDA) has granted full approval to lecanemab (Leqembi, Eisai/Biogen) and accelerated approval to donanemab (Kisunla, Eli Lilly) as disease-modifying therapies (per FDA approval records). In ALS/MND, riluzole and edaravone hold regulatory approval in multiple jurisdictions, and AMX0035 (Albrioza/Relyvrio) received FDA approval in 2022, though it was subsequently withdrawn from the US market by the sponsor in 2024 following a negative Phase 3 confirmatory trial (per Amylyx Pharmaceuticals public statement, 2024). EmtinB is listed as a preclinical asset and no clinical trial registration, partnership disclosures, or manufacturing agreements have been disclosed in the data provided. A June 2026 ASX announcement references 'Remarkable Results from Patients treated with StemSmart' and a January 2026 announcement references 'Successful Clinical Results Achieved under Special Access'; these appear to relate to a separate asset (StemSmart) rather than EmtinB, and no EmtinB-specific clinical data have been identified in the provided announcements. Whether EmtinB is the company's lead asset is not confirmed in the available data.